The early diagnosis of sepsis is hampered by the lack of reliable laboratory measures. There is growing evidence that presepsin and Mid-regional pro-adrenomedullin (MR-proADM) are promising biomarkers in the diagnosis of sepsis. This study was conducted to evaluate and compare the diagnostic value of MR-proADM and presepsin in sepsis patients.
We searched Web of Science, PubMed, Embase, China national knowledge infrastructure, and Wanfang up to 22th July, 2022, for studies evaluating the diagnosis performance of presepsin and MR-proADM in adult sepsis patients. Risk of bias was assessed using quadas-2. Pooled sensitivity and specificity were calculated using bivariate meta-analysis. Meta-regression and subgroup analysis were used to find source of heterogeneity.
A total of 40 studies were eventually selected for inclusion in this meta-analysis, including 33 for presepsin and seven for MR-proADM. Presepsin had a sensitivity of 0.86 (0.82–0.90), a specificity of 0.79 (0.71–0.85), and an AUC of 0.90 (0.87–0.92). The sensitivity of MR-proADM was 0.84 (0.78–0.88), specificity was 0.86 (0.79–0.91), and AUC was 0.91 (0.88–0.93). The profile of control group, population, and standard reference may be potential sources of heterogeneity.
This meta-analysis demonstrated that presepsin and MR-proADM exhibited high accuracy (AUC ≥ 0.90) in the diagnosis of sepsis in adults, with MR-proADM showing significantly higher accuracy than presepsin.
Sepsis, a complex disorder which progresses as a dysregulated host response to infections , is a major challenge in emergency departments and intensive care units. Despite progress in clinical support has been made through advances in antibacterial therapy, sepsis and its sequelae are still associated with a high risk of death [2, 3]. The accurate and rapid diagnosis of sepsis is often difficult in clinical practice as its clinical manifestation may be confused with other normal inflammatory response of uncomplicated infection , as well as the lack of diagnostic tools. A delayed diagnosis may result in a more serious condition, such as multiple system organ failure. Therefore, it is necessary to develop a reliable method to improve the diagnosis of sepsis.
Clinical decisions for sepsis treatment are usually based on the physician's experience due to the lack of rapid and accurate diagnosis tools. Although blood culture is commonly regarded as the "gold standard" for diagnosis of sepsis, it takes several days to obtain results and often produces false negative (FN) results due to the use of antibiotics. Moreover, false positive (FP) results may occur due to sample contamination . The use of biomarkers can greatly improve a physician's ability to accurately diagnose sepsis and initiate appropriate treatment. C-reactive protein (CRP) and procalcitonin (PCT) are among the most extensively studied biomarkers for sepsis diagnosis. However, the accuracy of sepsis prediction by CRP is limited by its low sensitivity , and the variation in reported cutoff values among studies greatly hinders the practical application of PCT in clinical settings . An ideal biomarker with adequate clinical accuracy for the diagnosis of sepsis is still needed.
Presepsin, also named as soluble CD14 subtype, is a N-terminal fragment of soluble CD14, which is released from the surface of immune cell lines after stimulation by pathogens. Serum presepsin can be easily detected . Level of presepsin increases within 2 h after the onset of infection and peaks at 3 h . The quick detection makes it a potential candidate biomarker for sepsis. However, the interpretation of elevated presepsin level requires special caution in several clinical conditions. Age (newborns and the elderly), acute pancreatitis, and burns can influence presepsin levels [9,10,11]. Furthermore, since presepsin is filtered by the glomerulus and reabsorbed by the proximal tubules, any condition that affects kidney filtrating function will have an impact on plasmatic presepsin. Mid-regional pro-adrenomedullin (MR-proADM), a peptide fragment of hormone adrenomedullin (ADM), has recently emerged as a promising diagnostic biomarker in the evaluation of sepsis. ADM is widely expressed in many organs and tissues. In healthy subjects, the plasma concentration of ADM is low, while during pathological events, the concentration is significantly increased. Changes in plasma concentration are proportional to the severity of the disease . Since ADM is rapidly cleared from the circulation which makes it hard to be detected, more stable MR-proADM directly reflects the level of ADM and is therefore used as an alternative. Burns are also associated with increased levels of MR-proADM .
The performance of the two novel biomarkers were unclear. Therefore, the objective of this meta-analysis was to determine and compare the diagnostic performance of presepsin and MR-proADM in sepsis.
This study followed the Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies (PRISMA-DTA) . The protocol was registered on PROSPERO with reference number CRD42022357335.
We searched Web of Science, PubMed, Embase, China national knowledge infrastructure (CNKI) and Wanfang up to 22th July, 2022. S1 table shows the complete search strategy. Briefly, population (adults with sepsis or septic shock), index test (MR-proADM and presepsin), comparison (adults not suffering from sepsis or septic shock), and outcome (diagnostic accuracy) were used.
A study was selected if it satisfied the following criteria: (1) purpose of the study was to evaluate diagnosis performance of presepsin or MR-proADM in sepsis or septic shock. (2) adult patients with sepsis or septic shock were included in the experimental group and patients with non-sepsis or healthy participants were in the control group; (3) a gold standard was clearly defined for the diagnosis of sepsis. The exclusion criteria were as follows: (1) there is no enough data to calculate diagnostic accuracy estimates; (2) conference abstracts, reviews, and editorials. Two independent reviewers (JL and YC) completed the study screening with disagreement resolved by consensus.
We extracted the following data by two independent reviewers (JL and YC): first author, year of publication, study design, region, sample size, severity of patient, sample type, assay methodology, standard reference, cut-off value, area under the curve (AUC), sensitivity, specificity. Disagreement was resolved by consensus.
Quality Assessment Tool for Diagnostic Accuracy Studies (QUADAS-2 score) was used for quality assessment . Risk of bias domains, including patient selection, index test, reference standard, flow and timing, and applicability concerns were evaluated. Two independent reviewers (YC and YS) completed the quality assessment with disagreement resolved by consensus.
The heterogeneity caused by non-threshold effects was measured using bivariate boxplot and I2. If I2 ≥ 50%, P values ≤ 0.05, or studies fall outside the bivariate boxplot, indicating significant heterogeneity due to non-threshold effects, then meta-regression or subgroup analysis is performed to identify the source of heterogeneity. Sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic ratio (DOR), AUC, and corresponding 95% confidence interval (CI) were calculated using a binary regression model of STATA 15.1 software using true positive (TP), FP, FN, and true negative (TN). Literature quality evaluation using Revman 5.4.1. Deek funnel diagrams were used to detect publication bias, with P < 0.05 indicating publication bias in the study.
Characteristics of the included studies
A total of 419 studies were included after the database search. Of these, 295 studies were excluded by the abstract screening, and 85 were excluded by the full-text screening (Fig. 1). Finally, 40 studies were included in this meta-analysis, with 33 for the diagnosis of presepsin and seven for MR-proADM (Table 1) [16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54].
In the 33 studies [16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48] evaluating the diagnostic performance of presepsin, 28 studies [16, 18,19,20,21,22, 24, 26,27,28, 30,31,32,33,34,35, 37, 38, 40,41,42,43,44,45,46,47,48] were prospective, three were retrospective, and two were unclear [29, 36]. Nineteen studies [16,17,18,19,20,21, 23,24,25, 28, 29, 36, 39, 41,42,43, 46,47,48] were conducted in Asia, nine in Europe [26, 27, 31, 32, 35, 38, 40, 44, 45], three in Africa [30, 33, 34], one in America , and one unclear . Fifteen studies used Sepsis-3 as the standard reference for sepsis diagnosis [27, 29, 44,45,46,47].
In the seven studies [35, 49,50,51,52,53,54] evaluating the diagnostic performance of MR-proADM, five studies [35, 49, 51, 53, 54] were prospective, one  were respective, and one were unclear . All the studies were conducted in Europe. Three studies [49, 53, 54] used Sepsis-3 as the standard reference for sepsis diagnosis.
Results of quality assessment
We assessed the quality of the literature using QADAS 2 and the results are shown in Additional file 5. Red, yellow, and green indicate high, medium, and low risk classifications, respectively. The graph shows the risk assessment for each of the 40 studies. In terms of risk of bias, four studies [28, 31, 33, 44] had unspecified bias in patient selection; 21 studies [17,18,19,20,21, 23, 25, 27,28,29,30, 36, 40,41,42, 44, 48, 50,51,52,53] had unspecified bias in index testing; one study  was assigned high bias in terms of reference standard; one study  was judged to be highly biased in terms of flow and timing. In terms of suitability, two studies [24, 47] had high bias in patient selection; three studies [24, 47, 52] were judged to have high bias relative to the index test; one study  had a high risk of suitability evaluation for the gold standard. Overall quality was good.
Diagnostic value of presepsin and MR-proADM
The forest plots and summary receiver operator characteristic curves (SROC) showing the diagnostic performance of biomarkers are illustrated in Fig. 2 for presepsin and Fig. 3 for MR-proADM. In the diagnosis of sepsis, presepsin achieved a pooled AUC of 0.90 (95% CI, 0.87–0.92), sensitivity of 0.86 (95% CI, 0.82–0.90), and specificity of 0.79 (95% CI, 0.71–0.85). For MR-proADM, the pooled AUC was 0.91 (95% CI, 0.88–0.93), sensitivity was 0.84 (95% CI, 0.78–0.88), and specificity was 0.86 (95% CI, 0.79–0.91).
Meanwhile, we compared presepsin with MR-proADM, and the results showed that the performance of the two biomarkers were statistically significant in terms of sensitivity, specificity and AUC (Table 2). The sensitivity of Presepsin was higher than MR-proADM (0.86 vs 0.84, P < 0.001), whereas the specificity of MR-proADM was higher than Presepsin (0.79 vs 0.86, P < 0.001). The AUC of MR-proADM was significantly higher than that of presepsin.
Subgroup analysis of presepsin
For Presepsin, we performed subgroup analyses (Table 3) and meta-regression analyses (Figure S1). It was found that population characteristics of control group, region of the dataset, reference standard of sepsis, and cutoff value influenced the pooled sensitivity of the included studies and were the possible sources of heterogeneity. The sensitivity of presepsin was significantly higher in non-Asian populations than in Asian populations (0.90 vs. 0.84), and was significantly higher in studies using patients with non-sepsis disease as control group than healthy subjects as control group. Furthermore, studies using cutoff value < 445 ng/L showed slightly higher sensitivity than the studies with cutoff value greater than 445, while the difference in specificity between the two groups was not statistically significant.
The sensitivity analysis in Figure S2 was performed to investigate the robust of our study. When seven outlier studies were excluded, the overall results were only minimally changed, suggesting that our results were not driven by these outlying points, which indicated that our study is robust. The bivariate box plot with most studies clustering within the median distribution suggested an acceptable degree of heterogeneity (Figure S3).
Risk of publication bias
We performed published bias analysis and the results (Fig. 4) showed no published bias.
This meta-analysis compared the performance of two novel biomarkers, presepsin and MR-proADM, in the diagnosis of sepsis. Both biomarkers showed good diagnostic performance, with AUC being 0.90 for presepssin and 0.91 for MR-proADM, proving their potential value in the assistance of sepsis diagnosis.
Clinically, early and accurate diagnosis of sepsis may be challenging. Conventional inflammatory biomarkers, such as CRP and PCT, have been extensively studied and applied in patients with sepsis. In several clinical studies, PCT was found to be more accurate than CRP in differentiating sepsis and SIRS [55, 56]. In a previous meta-analysis , the sensitivity and specificity were 0.80 (95% CI, 0.63–0.90) and 0.61 (95% CI, 0.50–0.72), respectively, for the diagnosis of sepsis using CRP, and 0.80 (95% CI, 0.69–0.87) and 0.77 (95% CI, 0.60–0.88), respectively, using PCT. In this study, sensitivity is 0.86 for presepsin and 0.84 for MR-proADM, and specificity is 0.79 and 0.86, respectively. Compared to PCT, the two novel biomarkers showed higher diagnostic accuracy. In addition, presepsin levels rise earlier than CRP or PCT in response to sepsis , which indicated their potential values as biomarkers for early diagnosis of sepsis. In addition, it has been reported that MR-proADM levels are not affected by the type of pathogen involved compared with PCT, but instead reflect the degree of organ failure and disease severity . In contrast, previous studies have demonstrated that levels of PCT in patients with sepsis vary depending on the type of pathogen, with the highest levels observed in cases of gram-negative infections and lower levels seen in cases of yeast and intracellular germs [60, 61]. MR-proADM could provide broader and more reliable diagnostic and prognostic information.
The cause of sepsis should be considered for better diagnosis and management. Presepsin and MR-proADM are biomarkers that have been shown to be elevated in patients with sepsis triggered by bacterial infections. However, bacteria are not the only causative microbial pathogens. The diagnostic accuracy for sepsis caused by viruses, parasites, and fungi has not been well established yet. Angeletti et al.  conducted a study on a cohort of 200 patients with sepsis, categorized based on the source of the infection (Gram-positive and Gram-negative bacteria, yeast, or multiple microorganisms). The results showed that the MR-proADM had high diagnostic accuracy, with an AUC of 0.96 (p < 0.01), 0.94 (p < 0.001), 0.99 (p < 0.001), and 0.98 (p < 0.001) for the respective group. This study proved the potential value of MR-proADM in the diagnosis of sepsis caused by fungus. Additionally, presepsin levels were found to be elevated in patients with fungemia  and viral meningitis . MR-proADM levels were found to be elevated in diseases caused by viral and fungal infections, such as invasive fungal diseases , COVID-19 , dengue hemorrhagic fever , and influenza A pneumonia . Therefore, we recommended more studies investigate the value of presepsin and MR-proADM on the diagnosis of sepsis caused by pathogens other than bacteria, such as viruses, fungus and parasites.
Cut off values of presepsin for diagnosing sepsis are not always consistent among studies despite using the same assay, which hinders greatly in the clinical application of these biomarkers. In our study, the cut-off values reported range from 89.26 to 1,315 pg/mL for presepsin and 0.8 to 1.165 pg/mL for MR-proADM. Reasons for the wide range of cut off values may be differences in sepsis severity, study design, clinical settings, and type of samples. Specifically, patient inclusion criteria may be one of the main reason accounting for this discrepancy. It has been reported that in cases of chronic renal failure, resuscitations and trauma, presepsin levels may be falsely elevated . Therefore, the effects of comorbidities on presepsin levels should be considered in future study to confirm a clinically useful cutoff value.
We observed heterogeneity among the included studies for the following possible reasons: First, the standard definition of sepsis has been updated thrice over the past decades, which results in the different reference standards used across studies. The latest international consensus on sepsis, sepsis-3, was developed to further refine sepsis, with a greater focus on identifying organ dysfunction in infection-related situations . The broad definition of sepsis is a common limitation in all studies regarding the diagnosis of sepsis. Second, non-sepsis patients and healthy volunteers were evaluated as control groups, which may contribute to higher pooled outcomes than the real results . Furthermore, some studies identify sepsis only through blood culture, microscopy or positive PCR, while others comprehensively assess patients and combine clinical, radiological and laboratory data. Taken together, individual patient differences, criteria for sepsis diagnosis, methods for testing samples, laboratory levels of testing, and differences in the instruments used are possible sources of heterogeneity. Under this consequence, it is recommended that the more rigorous study design, including but not limited to the procedure of patient selection, and timing of measurement, be applied in future work investigating the diagnostic value of biomarkers for sepsis to improve their validity.
Considering the good performance observed in this study, presepsin and MR-proADM can serve as candidate biomarkers for sepsis. However, several aspects need to be further explored to fully verify their utility in clinical practice. First, prospective studies with large sample size is needed. Second, antibiotic treatment lowers the serum level of presepsin [71,72,73]. It is necessary to consider this factor and perform sequential measurements of serum presepsin during the period of treatment as limited medicine information of patients is recorded in previous studies. Additionally, previous studies have proved the potential valued of presepsin as a reliable biomarker for antibiotic stewardship. A study conducted by Masson et al.  indicated that monitoring presepsin levels during the initial week of treatment could serve as a reliable indicator of the effectiveness of the antimicrobial treatment. A recent multicenter, prospective cohort trial revealed that the use of presepsin to guide antibiotic prescriptions in sepsis patients resulted in significant reductions in the duration of antibiotic treatment, ICU or hospital stay, and hospitalization costs, without increasing mortality rates, recurrent infections, or the risk of worsening organ failure . Therefore, presepsin may not only be a promising biomarker for the diagnosis of sepsis, but also the management of antibiotic therapy. Finally, combination of the two biomarkers may be considered in future researches to achieve better diagnosis performance.
To the best of our knowledge, this is the first meta-analysis comparing the diagnostic performance of presepsin and MR-proADM in sepsis. The effects of several possible confounders on the outcome were evaluated by subgroup analysis. Nevertheless, several limitations exist. Firstly, only 7 studies evaluating the diagnostic value of MR-proADM were included in this study, as there was relatively little data available. Secondly, inclusion and exclusion criteria vary largely among the included studies. The above factors may cause risk of bias to the results of the present study.
This meta-analysis indicated that both presepsin and MR-proADM exhibited high accuracy for the diagnosis of sepsis in adults. MR-proADM is significantly more accurate than presepsin. Future clinical trials are necessary to further verify their utility in clinical practice.
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Positive likelihood ratio
Negative likelihood ratio
Summary receiver operator characteristic curves
C reactive protein
Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369:840–51.
Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303–10.
Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546–54.
Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13:426–35.
Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the Systemic Inflammatory Response Syndrome (SIRS). Aprospect Study Jama. 1995;273:117–23.
Standage SW, Wong HR. Biomarkers for pediatric sepsis and septic shock. Expert Rev Anti Infect Ther. 2011;9:71–9.
van Rossum AM, Wulkan RW, Oudesluys-Murphy AM. Procalcitonin as an early marker of infection in neonates and children. Lancet Infect Dis. 2004;4:620–30.
Chenevier-Gobeaux C, Borderie D, Weiss N, Mallet-Coste T, Claessens YE. Presepsin (sCD14-ST), an innate immune response marker in sepsis. Clin Chim Acta. 2015;450:97–103.
Piccioni A, Santoro MC, de Cunzo T, Tullo G, Cicchinelli S, Saviano A, et al. Presepsin as early marker of sepsis in emergency department: a narrative review. Medicina (Kaunas). 2021;57:770.
Xiao HL, Wang GX, Wang Y, Tan ZM, Zhou J, Yu H, et al. Dynamic blood presepsin levels are associated with severity and outcome of acute pancreatitis: A prospective cohort study. World J Gastroenterol. 2022;28:5203–16.
Hayashi M, Yaguchi Y, Okamura K, Goto E, Onodera Y, Sugiura A, et al. A case of extensive burn without sepsis showing high level of plasma presepsin (sCD14-ST). Burns Open. 2017;1:33–6.
Saeed K, Legramante JM, Angeletti S, Curcio F, Miguens I, Poole S, et al. Mid-regional pro-adrenomedullin as a supplementary tool to clinical parameters in cases of suspicion of infection in the emergency department. Expert Rev Mol Diagn. 2021;21:397–404.
Gille J, Ostermann H, Dragu A, Sablotzki A. MR-proADM: a new biomarker for early diagnosis of sepsis in burned patients. J Burn Care Res. 2017;38:290–8.
McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, and the P-DTAG, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA. 2018;319:388–96.
Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–36.
Lee S, Song J, Park DW, Seok H, Ahn S, Kim J, et al. Diagnostic and prognostic value of presepsin and procalcitonin in non-infectious organ failure, sepsis, and septic shock: a prospective observational study according to the Sepsis-3 definitions. BMC Infect Dis. 2022;22:8.
Kang ES, Lee JH. Diagnostic value of presepsin in odontogenic infection: a retrospective study. Maxillofac Plast Reconstr Surg. 2022;44:22.
Jeong YK, Kim EY. Predictive role of changes in presepsin and early sepsis in ICU Patients after abdominal surgery. J Surg Res. 2022;278:207–15.
Tahmaz A, ÖZtoprak N, Kizilates F. Investigation of Plasma Preseptin (sCD14-ST) Levels in Sepsis. Mediterranean Journal of Infection Microbes and Antimicrobials. 2022;11:11.
Chen J, Huang ZB, Li H, Zheng X, Chen JJ, Wang XB, et al. Early diagnostic biomarkers of sepsis for patients with acute-on-chronic liver failure: a multicenter study. Infect Dis Ther. 2021;10:281–90.
Yonaha T, Maruta T, Otao G, Igarashi K, Nagata S, Yano T, et al. The diagnostic and prognostic value of mature and total adrenomedullin for sepsis: a prospective observational study. Anaesthesiol Intensive Ther. 2021;53:411–7.
Abdelshafey EE, Nasa P, Elgohary AE, Khalil MF, Rashwan MA, Ghezala HB, et al. Role of presepsin for the diagnosis of sepsis and ICU mortality: a prospective controlled study. Indian J Crit Care Med. 2021;25:153–7.
Liu C, Qiu Q. Diagnostic value of PCT, SAA and presepsin in acute sepsis patients. Int J Clin Exp Med. 2020;13:9607–13.
Yamamoto T, Nishimura T, Kaga S, Uchida K, Tachibana Y, Esaki M, et al. Diagnostic accuracy of presepsin for sepsis by the new Sepsis-3 definitions. Am J Emerg Med. 2019;37:1936–41.
Nakamura Y, Hoshino K, Kiyomi F, Kawano Y, Mizunuma M, Tanaka J, et al. Comparison of accuracy of presepsin and procalcitonin concentrations in diagnosing sepsis in patients with and without acute kidney injury. Clin Chim Acta. 2019;490:200–6.
Juroš GF, Nikić MT, Šarić SD, Perić M, Rogić D. Contribution of presepsin, procalcitonin and C-reactive protein to the SOFA score in early sepsis diagnosis in emergency abdominal surgical patients. Signa Vitae: J Intesive Care Emerg Med. 2019;15:38–45.
Jereb M, Mavric M, Skvarc M, Drobnic A, Dolenc S, Strunjas NP, et al. Usefulness of presepsin as diagnostic and prognostic marker of sepsis in daily clinical practice. J Infect Dev Ctries. 2019;13:1038–44.
Lu B, Zhang Y, Li C, Liu C, Yao Y, Su M, et al. The utility of presepsin in diagnosis and risk stratification for the emergency patients with sepsis. Am J Emerg Med. 2018;36:1341–5.
Li H, Wu S. Prognostic value of soluble cluster differentiation antigen 14 subtype and platelet activating factor in patients with septic shock. Int J Clin Exp Med. 2018;11:8345–51.
El-Shafie ME-S, Taema KM, El-Hallag MM, Kandeel AMA. Role of presepsin compared to C-reactive protein in sepsis diagnosis and prognostication. Egypt J Critical Care Med. 2017;5:1–12.
de Guadiana Romualdo LG, Torrella PE, Acebes SR, Otón MDA, Sánchez RJ, Holgado AH, et al. Diagnostic accuracy of presepsin (sCD14-ST) as a biomarker of infection and sepsis in the emergency department. Clin Chim Acta. 2017;464:6–11.
Klouche K, Cristol JP, Devin J, Gilles V, Kuster N, Larcher R, et al. Diagnostic and prognostic value of soluble CD14 subtype (Presepsin) for sepsis and community-acquired pneumonia in ICU patients. Ann Intensive Care. 2016;6:59.
Ali FT, Ali MA, Elnakeeb MM, Bendary HN. Presepsin is an early monitoring biomarker for predicting clinical outcome in patients with sepsis. Clin Chim Acta. 2016;460:93–101.
Amer HA, Ghareeb H, Lotfy NM, El-Azizi NO, Mahmoud AM. Presepsin a diagnostic marker for sepsis in intensive care unit patients. Egypt J Immunol. 2016;23:109–18.
Enguix-Armada A, Escobar-Conesa R, García-De La Torre A, De La Torre-Prados MV. Usefulness of several biomarkers in the management of septic patients: C-reactive protein, procalcitonin, presepsin and mid-regional pro-adrenomedullin. Clin Chem Lab Med (CCLM). 2016;54:163–8.
Sato M, Takahashi G, Shibata S, Onodera M, Suzuki Y, Inoue Y, et al. Clinical performance of a new soluble CD14-subtype immunochromatographic test for whole blood compared with chemiluminescent enzyme immunoassay: use of quantitative soluble CD14-subtype immunochromatographic tests for the diagnosis of sepsis. PLoS ONE. 2015;10:e0143971.
Carpio R, Zapata J, Spanuth E, Hess G. Utility of presepsin (sCD14-ST) as a diagnostic and prognostic marker of sepsis in the emergency department. Clin Chim Acta. 2015;450:169–75.
Sargentini V, Ceccarelli G, D’Alessandro M, Collepardo D, Morelli A, D’Egidio A, et al. Presepsin as a potential marker for bacterial infection relapse in critical care patients. a preliminary study. Clin Chem Lab Med (CCLM). 2015;53:567–73.
Popa TO, Cimpoesu D, Dorobat CM. Diagnostic and prognostic value of presepsin in the emergency department. Rev Med Chir Soc Med Nat Iasi. 2015;119:69–76.
Behnes M, Bertsch T, Lepiorz D, Lang S, Trinkmann F, Brueckmann M, et al. Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment. Crit Care. 2014;18:507.
Madenci ÖÇ, Yakupoğlu S, Benzonana N, Yücel N, Akbaba D, Kaptanağası AO. Evaluation of soluble CD14 subtype (presepsin) in burn sepsis. Burns. 2014;40:664–9.
Kweon OJ, Choi J-H, Park SK, Park AJ. Usefulness of presepsin (sCD14 subtype) measurements as a new marker for the diagnosis and prediction of disease severity of sepsis in the Korean population. J Crit Care. 2014;29:965–70.
Liu B, Chen YX, Yin Q, Zhao YZ, Li CS. Diagnostic value and prognostic evaluation of Presepsin for sepsis in an emergency department. Crit Care. 2013;17:R244.
Vodnik T, Kaljevic G, Tadic T, Majkic-Singh N. Presepsin (sCD14-ST) in preoperative diagnosis of abdominal sepsis. Clin Chem Lab Med. 2013;51:2053–62.
Ulla M, Pizzolato E, Lucchiari M, Loiacono M, Soardo F, Forno D, et al. Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a multicenter prospective study. Crit Care. 2013;17:R168.
Shozushima T, Takahashi G, Matsumoto N, Kojika M, Okamura Y, Endo S. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother. 2011;17:764–9.
Venugopalan DP, Pillai G, Krishnan S. Diagnostic value and prognostic use of presepsin versus procalcitonin in sepsis. Cureus. 2019;11:e5151.
Zhenyu L, Huajie Z, Jun Z, BIn C. Early diagnostic value and prognostic significance of serum presepsin (sCD14-ST) in sepsis. Chin J Emerg Med. 2016;25:896–902.
Martin-Fernandez M, Vaquero-Roncero LM, Almansa R, Gómez-Sánchez E, Martín S, Tamayo E, et al. Endothelial dysfunction is an early indicator of sepsis and neutrophil degranulation of septic shock in surgical patients. BJS open. 2020;4:524–34.
Angeletti S, Spoto S, Fogolari M, Cortigiani M, Fioravanti M, De Florio L, et al. Diagnostic and prognostic role of procalcitonin (PCT) and MR-pro Adrenomedullin (MR-pro ADM) in bacterial infectious. APMIS. 2015;123:740–8.
Angeletti S, Battistoni F, Fioravanti M, Bernardini S, Dicuonzo G. Procalcitonin and mid-regional pro-adrenomedullin test combination in sepsis diagnosis. Clin Chem Lab Med. 2013;51:1059–67.
Angeletti S, Dicuonzo G, Fioravanti M, De Cesaris M, Fogolari M, Lo Presti A, et al. Procalcitonin, MR-proadrenomedullin, and cytokines measurement in sepsis diagnosis: advantages from test combination. Dis Markers. 2015;2015:951532.
Spoto S, Nobile E, Carna EPR, Fogolari M, Caputo D, De Florio L, et al. Best diagnostic accuracy of sepsis combining SIRS criteria or qSOFA score with Procalcitonin and Mid-Regional pro-Adrenomedullin outside ICU. Sci Rep. 2020;10:16605.
Spoto S, Cella E, de Cesaris M, Locorriere L, Mazzaroppi S, Nobile E, et al. Procalcitonin and MR-proadrenomedullin combination with SOFA and qSOFA scores for sepsis diagnosis and prognosis: a diagnostic algorithm. Shock. 2018;50:44–52.
Simon L, Saint-Louis P, Amre DK, Lacroix J, Gauvin F. Procalcitonin and C-reactive protein as markers of bacterial infection in critically ill children at onset of systemic inflammatory response syndrome. Pediatr Crit Care Med. 2008;9:407–13.
Luzzani A, Polati E, Dorizzi R, Rungatscher A, Pavan R, Merlini A. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med. 2003;31:1737–41.
Tan M, Lu Y, Jiang H, Zhang L. The diagnostic accuracy of procalcitonin and C-reactive protein for sepsis: A systematic review and meta-analysis. J Cell Biochem. 2019;120:5852–9.
Okamura Y, Yokoi H. Development of a point-of-care assay system for measurement of presepsin (sCD14-ST). Clin Chim Acta. 2011;412:2157–61.
Valenzuela-Sánchez F, Valenzuela-Méndez B, Rodríguez-Gutiérrez JF, Estella-García Á, González-García M. New role of biomarkers: mid-regional pro-adrenomedullin, the biomarker of organ failure. Ann Transl Med. 2016;4:329.
Dou YH, Du JK, Liu HL, Shong XD. The role of procalcitonin in the identification of invasive fungal infection-a systemic review and meta-analysis. Diagn Microbiol Infect Dis. 2013;76:464–9.
Jeong S, Park Y, Cho Y, Kim HS. Diagnostic utilities of procalcitonin and C-reactive protein for the prediction of bacteremia determined by blood culture. Clin Chim Acta. 2012;413:1731–6.
Bamba Y, Moro H, Aoki N, Koizumi T, Ohshima Y, Watanabe S, et al. Increased presepsin levels are associated with the severity of fungal bloodstream infections. PLoS ONE. 2018;13:e0206089.
Nockher WA, Wick M, Pfister HW. Cerebrospinal fluid levels of soluble CD14 in inflammatory and non-inflammatory diseases of the CNS: upregulation during bacterial infections and viral meningitis. J Neuroimmunol. 1999;101:161–9.
Decker SO, Krüger A, Wilk H, Grumaz S, Vainshtein Y, Schmitt FCF, et al. New approaches for the detection of invasive fungal diseases in patients following liver transplantation-results of an observational clinical pilot study. Langenbecks Arch Surg. 2019;404:309–25.
Sozio E, Tascini C, Fabris M, D’Aurizio F, De Carlo C, Graziano E, et al. MR-proADM as prognostic factor of outcome in COVID-19 patients. Sci Rep. 2021;11:5121.
Michels M, Djamiatun K, Faradz SM, Koenders MM, de Mast Q, van der Ven AJ. High plasma mid-regional pro-adrenomedullin levels in children with severe dengue virus infections. J Clin Virol. 2011;50:8–12.
Valenzuela Sanchez F, Valenzuela Mendez B, Rodríguez Gutierrez J, de Bohollo Austria R, Rubio Quiñones J, Puget Martínez L, et al. Initial levels of mr-proadrenomedullin: a predictor of severity in patients with influenza a virus pneumonia. Int Care Med Exp. 2015;3:1–2.
Yang HS, Hur M, Yi A, Kim H, Lee S, Kim SN. Prognostic value of presepsin in adult patients with sepsis: Systematic review and meta-analysis. PLoS ONE. 2018;13:e0191486.
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801–10.
Wu J, Hu L, Zhang G, Wu F, He T. Accuracy of presepsin in sepsis diagnosis: a systematic review and meta-analysis. PLoS ONE. 2015;10:e0133057.
Ozdemir AA, Elgormus Y. Diagnostic value of presepsin in detection of early-onset neonatal sepsis. Am J Perinatol. 2017;34:550–6.
Poggi C, Bianconi T, Gozzini E, Generoso M, Dani C. Presepsin for the detection of late-onset sepsis in preterm newborns. Pediatrics. 2015;135:68–75.
Montaldo P, Rosso R, Santantonio A, Chello G, Giliberti P. Presepsin for the detection of early-onset sepsis in preterm newborns. Pediatr Res. 2017;81:329–34.
Masson S, Caironi P, Fanizza C, Thomae R, Bernasconi R, Noto A, et al. Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial. Intensive Care Med. 2015;41:12–20.
Xiao H, Wang G, Wang Y, Tan Z, Sun X, Zhou J, et al. Potential value of presepsin guidance in shortening antibiotic therapy in septic patients: a multicenter prospective cohort Trial. Shock. 2022;57:63–71.
Ethics approval and consent to participate
This study is a meta-analysis, which does not contain any human data, and the ethics approval and consent to participate are not applicable.
Consent for publication
This study is a meta-analysis, which does not contain any individual person’s data, and the consent for publication is not applicable.
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The result of meta-regression for presepsin.
Graphical depiction of residual-based goodness-of-fit, bivariate normality, influence and outlier detection analyses.
Bivariate boxplot for presepsin (A) and MR (B).
Search strategy used in this study
Quality assessment of the included studies.
About this article
Cite this article
Liang, J., Cai, Y. & Shao, Y. Comparison of presepsin and Mid-regional pro-adrenomedullin in the diagnosis of sepsis or septic shock: a systematic review and meta-analysis. BMC Infect Dis 23, 288 (2023). https://doi.org/10.1186/s12879-023-08262-4